Eli Lilly and Company (LLY) Stock: Rises as Taltz and Zepbound Show Promising Results

TLDR

• Eli Lilly stock gains 0.62% as new Phase 3b findings highlight treatment gains.
• Combined therapy changes 482 proteins versus 140 with Taltz alone by Week 36.
• Gene activity shifts span 467 genes with both drugs, versus 16 on Taltz alone.
• Taltz and Zepbound deliver improved skin clearance and weight loss at Week 36.
• Researchers report consistent safety findings, but no new approved indication.

Eli Lilly and Company stock rose 0.62% to $1,176.80 on Friday, gaining $7.20 during the trading session. The company announced new Phase 3b findings showing broader biological responses from combined Taltz and Zepbound treatment. The results expand earlier evidence of improved psoriasis symptoms and weight reduction among adults living with psoriasis and obesity.

Eli Lilly and Company, LLY

Eli Lilly Reports Stronger Phase 3b Results for Taltz and Zepbound

Eli Lilly released new exploratory findings from its TOGETHER-PsO Phase 3b clinical trial examining two existing prescription medicines. Researchers compared the combined use of Taltz and Zepbound against Taltz alone in adults with moderate-to-severe plaque psoriasis. The study also included participants with obesity or overweight alongside at least one additional weight-related medical condition.

The latest analysis identified broader changes in proteins and genes among participants receiving both medicines compared with Taltz alone. By Week 36, researchers identified changes involving 482 proteins in the combination group, compared with 140 in the other group. Similarly, gene expression changes affected 467 genes with combined treatment, against only 16 genes with Taltz alone.

These biological differences appeared as early as Week 12, according to the pharmaceutical company’s newly released findings. Researchers also identified stronger reductions in inflammatory immune activity among participants receiving both treatments over the study period. Eli Lilly presented the findings at the 2026 Fall Clinical Dermatology Conference in Las Vegas.

Combined Treatment Improves Skin Clearance and Weight Reduction

The latest findings build on earlier clinical results showing better treatment outcomes among participants receiving Taltz alongside Zepbound. At Week 36, the combination delivered superior skin clearance and meaningful weight reduction compared with Taltz alone. Furthermore, participants maintained or improved these clinical benefits through Week 52, according to Eli Lilly’s previously reported findings.

The analysis also examined neutrophils, which play an important role in the body’s inflammatory immune response. Researchers found that combined treatment produced greater changes in inflammatory pathways associated with these immune cells. Changes in certain neutrophil-related markers partly explained the additional improvement in psoriasis severity scores among combination-treatment participants.

The TOGETHER-PsO trial included 274 adults across multiple clinical research centers, with participants divided equally between two treatment groups. One group received Taltz alone, while the other received Taltz and Zepbound through injections under the skin. Both groups also received guidance on reducing calorie intake and increasing physical activity throughout the clinical study.

Eli Lilly Expands Research Into Psoriasis and Obesity

Eli Lilly designed the study to examine the relationship between metabolic health and inflammatory skin conditions. Approximately 61% of Americans with psoriasis also experience obesity or overweight alongside another weight-related medical condition, according to Lilly. The findings provide additional research into how treatments targeting different biological processes may influence both conditions.

Taltz works by blocking interleukin-17A, an immune signaling protein involved in inflammation and several related inflammatory conditions. Zepbound targets GIP and GLP-1 receptors, helping regulate appetite and support weight management in eligible adults. The two medicines therefore act through different biological pathways, providing the basis for investigating their combined clinical effects.

Eli Lilly reported that the combination’s safety findings matched the established safety profiles of the individual medicines. The exploratory results do not establish a new approved indication for using the medicines together. The company continues examining the relationship between immune and metabolic processes as researchers assess broader approaches to psoriasis management.

The post Eli Lilly and Company (LLY) Stock: Rises as Taltz and Zepbound Show Promising Results appeared first on Blockonomi.